CollPlant to Present at the 2025 International Conference on Biofabrication
MWN-AI** Summary
CollPlant Biotechnologies, a dynamic company specializing in regenerative and aesthetic medicine, has announced its participation in the 2025 International Conference on Biofabrication, organized by the International Society for Biofabrication (ISBF). This prestigious event will be held from September 14–17, 2025, at the Palace of Culture and Science in Warsaw, Poland.
CollPlant is set to make two significant presentations during the conference. On September 16, CEO Yehiel Tal will chair the “Industrial Session” where the company will present "rhCollagen Bioinks for Biofabrication." This presentation will showcase the capabilities of CollPlant’s recombinant human collagen (rhCollagen) bioinks, which provide advantageous properties such as controlled rheology, biocompatibility, and a non-animal safety profile. The following day, CollPlant will present "Mechanical Computational Modeling and Simulation of Biodegradable Implants," further contributing to the conversation on tissue engineering and biofabrication technologies.
In addition to the presentations, CollPlant will host an exhibition booth throughout the conference, which will feature its groundbreaking rhCollagen platform and various biofabrication applications. With the rapid advancement of 3D bioprinting technologies, CollPlant’s innovations are at the forefront of enabling the creation of complex scaffolds vital for tissue and organ engineering.
The ISBF, committed to enhancing biofabrication research and education, facilitates annual conferences that allow professionals and researchers to collaborate and exchange ideas in this rapidly evolving field. As the 2025 conference anticipates participation from over 500 attendees globally, CollPlant’s presence underscores its commitment to advancing medical solutions through sustainable, plant-based technologies.
For more information, visit CollPlant’s website at http://www.collplant.com.
MWN-AI** Analysis
CollPlant Biotechnologies (Nasdaq: CLGN) is poised for a pivotal moment with its participation in the 2025 International Conference on Biofabrication in Warsaw, Poland, where it plans to showcase its innovative rhCollagen-based technologies. As a financial analyst, I recommend investors closely monitor CollPlant's developm?nts both at this conference and in its ongoing partnerships and product applications.
The company’s presentations on “rhCollagen Bioinks for Biofabrication” and “Mechanical Computational Modeling and Simulation of Biodegradable Implants” signal a strategic focus on the growing field of 3D bioprinting, which could redefine medical aesthetics and regenerative medicine markets. CollPlant’s rhCollagen, derived from a non-animal source, offers a unique value proposition with improved safety and biocompatibility, making it an attractive alternative in the biofabrication landscape.
With the global demand for innovative healthcare solutions rising, particularly in the regenerative medicine sector, CollPlant's technologies position it well to capitalize on emerging trends. The collaboration with AbbVie enhances its market credibility and financial outlook; however, investors must remain cognizant of inherent risks, including regulatory hurdles and the necessity for ongoing capital.
As the bioprinting industry expands, the visibility CollPlant gains at international conferences can bolster its reputation and potentially attract additional partnerships. Investors should watch for new announcements following the conference, as successful engagement could lead to enhanced stock performance.
In conclusion, while challenges remain, CollPlant’s focus on innovation and strategic partnerships may provide a favorable outlook. Observing the outcome of their conference presentations and subsequent developments will be key for informed investment decisions in this dynamic sector. Maintaining a balanced view of both risks and opportunities is essential for navigating the potential volatility of CollPlant's stock.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
PR Newswire
REHOVOT, Israel , Sept. 2, 2025 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetic medicine company developing disruptive technologies and products based on its non-animal-derived recombinant human collagen (rhCollagen), today announced its participation in the annual meeting of The International Society of Biofabrication: the International Conference on Biofabrication 2025, to be held September 14–17, 2025, at the Palace of Culture and Science in Warsaw, Poland .
CollPlant is scheduled to have two presentations at the Conference:
Tuesday, September 16 th
- Presentation title: "rhCollagen Bioinks for Biofabrication"
- Presentation time: This presentation will be made during the "Industrial Session" from 1:30 p.m. to 3:00 p.m.
- The session will be chaired by CollPlant's CEO, Yehiel Tal .
Wednesday, September 17 th
- Presentation title: "Mechanical Computational Modeling and Simulation of Biodegradable Implants"
- Presentation time: This presentation will be from 1:50 p.m. to 2:00 p.m.
Throughout the conference, CollPlant will host an exhibition booth featuring its rhCollagen platform and biofabrication applications. As 3D bioprinting gains momentum across medical research - enabling fabrication of complex scaffolds for tissue and organ engineering - CollPlant's rhCollagen-based bioinks offer the key attributes for high-fidelity printing: controlled rheology, a non-animal safety profile, biocompatibility, and tunable mechanical properties.
About the International Society for Biofabrication and its Annual Conference
The International Society for Biofabrication (ISBF) is a non-profit scientific organization founded in 2010 that promotes advancements in biofabrication research, development, education, training, and clinical applications, including 3D printing of tissues and regenerative medicine. The ISBF hosts an annual International Conference on Biofabrication , publishes the journal Biofabrication , and aims to foster collaboration and recognize excellence within the global biofabrication community.
The ISBF organizes the International Conference on Biofabrication annually , to discuss research related to biofabrication and bioprinting and provide a platform for researchers and professionals to share findings and discuss future directions. Since the first meeting in 2006 in Manchester the conference has grown into an annual event with more than 500 participants from dozens of countries.
About CollPlant
CollPlant is a regenerative and aesthetic medicine company ushering in a new era of medical solutions with a focus on 3D bioprinting of tissues and organs, tissue repair and medical aesthetics. The Company's products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant-based genetic engineering technology. These products address indications within the diverse fields of tissue repair, aesthetics, and organ manufacturing.
In 2021, CollPlant entered into a development and global commercialization agreement for dermal and soft tissue fillers with Allergan, an AbbVie company, the global leader in the dermal filler market.
For more information about CollPlant, visit http://www.collplant.com .
Forward-Looking Statements
This press release may include forward-looking statements. Forward-looking statements may include, but are not limited to, statements relating to CollPlant's objectives plans and strategies, as well as statements, other than historical facts, that address activities, events or developments that CollPlant intends, expects, projects, believes or anticipates will or may occur in the future. These statements are often characterized by terminology such as "believes," "hopes," "may," "anticipates," "should," "intends," "plans," "will," "expects," "estimates," "projects," "positioned," "strategy" and similar expressions and are based on assumptions and assessments made in light of management's experience and perception of historical trends, current conditions, expected future developments and other factors believed to be appropriate.
Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements. Many factors could cause CollPlant's actual activities or results to differ materially from the activities and results anticipated in forward-looking statements, including, but not limited to, the following: the Company's history of significant losses, its need to raise additional capital and its inability to obtain additional capital on acceptable terms, or at all; the Company's expectations regarding the costs and timing of commencing and/or concluding pre-clinical and clinical trials with respect to breast implants, tissues and organs which are based on its rhCollagen based BioInk and other products for medical aesthetics, and specifically the Company's ability to initiate its next large-animal study for its breast implants in a timely manner, or at all; the Company's or it strategic partners' ability to obtain favorable pre-clinical and clinical trial results; regulatory action with respect to rhCollagen based bioink and medical aesthetics products or product candidates including, but not limited to acceptance of an application for marketing authorization review and approval of such application, and, if approved, the scope of the approved indication and labeling; commercial success and market acceptance of the Company's rhCollagen based products, in 3D bioprinting and medical aesthetics; the Company's ability to establish sales and marketing capabilities or enter into agreements with third parties and its reliance on third party distributors and resellers; the Company's ability to establish and maintain strategic partnerships and other corporate collaborations, including its partnership with AbbVie and its ability to continue to receive milestone and royalties payments under the AbbVie agreement; the Company's reliance on third parties to conduct some or all aspects of its product development and manufacturing; the scope of protection the Company is able to establish and maintain for intellectual property rights and the Company's ability to operate its business without infringing the intellectual property rights of others; current or future unfavorable economic and market conditions and adverse developments with respect to financial institutions and associated liquidity risk; the impact of competition and new technologies; general market, political, and economic conditions in the countries in which the Company operates, including, with respect to the ongoing war in Israel , projected capital expenditures and liquidity, changes in the Company's strategy, and litigation and regulatory proceedings. More detailed information about the risks and uncertainties affecting CollPlant are contained under the heading "Risk Factors" included in CollPlant's most recent annual report on Form 20-F filed with the SEC, and in other filings that CollPlant has made and may make with the SEC in the future. The forward-looking statements contained in this press release are made as of the date of this press release and reflect CollPlant's current views with respect to future events, and CollPlant does not undertake and specifically disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Contacts
CollPlant:
Eran Rotem
Deputy CEO & CFO
+ 972-73-2325600
Eran@collplant.com
Investors:
LifeSci Advisors
Dan Ferry
daniel@lifesciadvisors.com
Photo - https://mma.prnewswire.com/media/2762352/CollPlant_Exhibition.jpg
Logo - https://mma.prnewswire.com/media/2217353/CollPlant_Logo.jpg
SOURCE CollPlant
FAQ**
What innovative applications for rhCollagen does CollPlant Holdings Ltd. CLGN plan to showcase at the 2025 International Conference on Biofabrication, particularly regarding the biofabrication of complex scaffolds for tissue engineering?
How does CollPlant Holdings Ltd. CLGN plan to address potential regulatory challenges for its rhCollagen-based products presented at the biofabrication conference, especially concerning approvals for clinical trials?
In what ways does CollPlant Holdings Ltd. CLGN's partnership with AbbVie enhance its competitive position in the biofabrication market, particularly concerning the commercialization of its rhCollagen products?
What specific outcomes does CollPlant Holdings Ltd. CLGN aim to achieve from its presentations at the International Conference on Biofabrication, and how do these align with the company's long-term strategic goals?
**MWN-AI FAQ is based on asking OpenAI questions about CollPlant Holdings Ltd. (NASDAQ: CLGN).
NASDAQ: CLGN
CLGN Trading
-2.38% G/L:
$0.6101 Last:
1,812 Volume:
$0.61 Open:
